RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
GlaxoSmithKline Pharmaceuticals Stock

GlaxoSmithKline Pharmaceuticals Equity 2025

GlaxoSmithKline Pharmaceuticals Equity

17.78 B INR

Ticker

GLAXO.NS

ISIN

INE159A01016

In 2025, GlaxoSmithKline Pharmaceuticals's equity was 17.78 B INR, a 2.09% increase from the 17.41 B INR equity in the previous year.

GlaxoSmithKline Pharmaceuticals Aktienanalyse

What does GlaxoSmithKline Pharmaceuticals do?

GlaxoSmithKline (GSK) is a global pharmaceutical company focused on the development, manufacturing, and marketing of prescription medicines, vaccines, and consumer products. Founded in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, the company has become one of the leading players in the pharmaceutical and healthcare industry. GSK's history began in 1859 with the opening of a pharmacy in New Zealand by Joseph Edward Nathan. In 1904, physician and researcher Joseph Nathan Cohen founded Glaxo Laboratories, which specialized in the production of vitamin preparations. Over the years, the company expanded and eventually merged with Wellcome plc in 1995 to form Glaxo Wellcome. SmithKline Beecham was founded in 1830 and expanded through acquisitions and mergers in the following decades. In June 2000, Glaxo Wellcome and SmithKline Beecham merged to form GlaxoSmithKline. GSK's business model is based on research, development, and marketing of products aimed at improving patients' lives. The company has a wide range of products, including prescription medicines, vaccines, and consumer products. GSK operates in over 100 countries and employs over 100,000 people worldwide. GSK has various divisions, including pharmaceuticals, vaccines, and consumer healthcare. The pharmaceutical division is the company's core business and focuses on researching and developing innovative therapies in the areas of oncology, immunology, infectious diseases, and respiratory diseases. The company's vaccine division is involved in vaccine production and the development of new vaccine technologies. GSK is one of the largest vaccine manufacturers globally and produces vaccines against infectious diseases such as hepatitis A and B, meningococcal disease, pneumococcal disease, and HPV. The company's consumer healthcare division produces a wide range of products in the health and wellness sector, including dietary supplements, pain relievers, and skincare products under brands like Sensodyne, Voltaren, and Aquafresh. Some of GSK's most well-known products include the antidepressant Paxil, the asthma inhaler Advair, and the antimalarial medication Malarone. Additionally, GSK has played a leading role in addressing global health issues, such as developing a vaccine against Ebola and providing antiretroviral drugs for the treatment of HIV/AIDS. Overall, GlaxoSmithKline has established a strong position as one of the leading global pharmaceutical companies in recent years. The company pursues an innovative research and development strategy to promote forward-looking technologies that have the potential to change the way we perceive and treat diseases. With a strong focus on innovation, growth, and improving the quality of life for patients worldwide, GSK is on track to remain a significant player in the global healthcare industry. GlaxoSmithKline Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing GlaxoSmithKline Pharmaceuticals's Equity

GlaxoSmithKline Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding GlaxoSmithKline Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating GlaxoSmithKline Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

GlaxoSmithKline Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in GlaxoSmithKline Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about GlaxoSmithKline Pharmaceuticals stock

What is the equity of GlaxoSmithKline Pharmaceuticals this year?

GlaxoSmithKline Pharmaceuticals has equity of 17.78 B INR this year.

What was the equity of GlaxoSmithKline Pharmaceuticals compared to the previous year?

The equity of GlaxoSmithKline Pharmaceuticals has increased/decreased by 2.09% increased compared to the previous year.

What impact does a high equity have on investors of GlaxoSmithKline Pharmaceuticals?

A high equity is advantageous for investors of GlaxoSmithKline Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of GlaxoSmithKline Pharmaceuticals?

A low equity can be a risk for investors of GlaxoSmithKline Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of GlaxoSmithKline Pharmaceuticals affect the company?

An increase in equity of GlaxoSmithKline Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of GlaxoSmithKline Pharmaceuticals affect the company?

A reduction in equity of GlaxoSmithKline Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of GlaxoSmithKline Pharmaceuticals?

Some factors that can affect the equity of GlaxoSmithKline Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of GlaxoSmithKline Pharmaceuticals so important for investors?

The equity of GlaxoSmithKline Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can GlaxoSmithKline Pharmaceuticals take to change the equity?

To change equity, GlaxoSmithKline Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does GlaxoSmithKline Pharmaceuticals pay?

Over the past 12 months, GlaxoSmithKline Pharmaceuticals paid a dividend of 44 INR . This corresponds to a dividend yield of about 2.25 %. For the coming 12 months, GlaxoSmithKline Pharmaceuticals is expected to pay a dividend of 30.56 INR.

What is the dividend yield of GlaxoSmithKline Pharmaceuticals?

The current dividend yield of GlaxoSmithKline Pharmaceuticals is 2.25 %.

When does GlaxoSmithKline Pharmaceuticals pay dividends?

GlaxoSmithKline Pharmaceuticals pays a quarterly dividend. This is distributed in the months of August, July, June, December.

How secure is the dividend of GlaxoSmithKline Pharmaceuticals?

GlaxoSmithKline Pharmaceuticals paid dividends every year for the past 23 years.

What is the dividend of GlaxoSmithKline Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 30.56 INR are expected. This corresponds to a dividend yield of 1.56 %.

In which sector is GlaxoSmithKline Pharmaceuticals located?

GlaxoSmithKline Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von GlaxoSmithKline Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GlaxoSmithKline Pharmaceuticals from 11/28/2024 amounting to 12 INR, you needed to have the stock in your portfolio before the ex-date on 11/7/2024.

When did GlaxoSmithKline Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/28/2024.

What was the dividend of GlaxoSmithKline Pharmaceuticals in the year 2024?

In the year 2024, GlaxoSmithKline Pharmaceuticals distributed 32 INR as dividends.

In which currency does GlaxoSmithKline Pharmaceuticals pay out the dividend?

The dividends of GlaxoSmithKline Pharmaceuticals are distributed in INR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von GlaxoSmithKline Pharmaceuticals

Our stock analysis for GlaxoSmithKline Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GlaxoSmithKline Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.